Mankind Pharma Quarterly Results for Trading Insights
In Mar 2026, Mankind Pharma (MANKIND) reported revenue ₹3,560 Cr and net profit ₹559 Cr — revenue +6.8% YoY. Also explore MANKIND price movement history to track price trends across different timeframes.
MANKIND Quarterly Results — Revenue, Profit & EPS Highlights
Mankind Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Browse MANKIND cash flow statement for revenue, profit, balance sheet and cash flow data.
- Revenue of ₹3,560 Cr in Mar 2026 (-6.1% vs Sept 2025, +6.8% vs Mar 2025)
- Net Profit of ₹559 Cr in Mar 2026 (+7.5% vs Sept 2025, +31.5% vs Mar 2025)
- EBITDA of ₹1,024 Cr in Mar 2026 (+0.8% vs Sept 2025)
- Operating Margin of 26.0% in Mar 2026 (+1.0pp vs Sept 2025)
- Earnings Per Share of ₹13.44 in Mar 2026 (+8.5% vs Sept 2025)
Mankind Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS
MANKIND quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 3,560 | 3,791 | 3,333 | 3,653 | 3,643 | -6.1% | 6.8% |
| Net Profit (₹ Cr) | 559 | 520 | 425 | 445 | 414 | - | - |
| EBITDA (₹ Cr) | 1,024 | 1,016 | 933 | 930 | 889 | - | - |
| EPS (₹) | 13.44 | 12.39 | 10.19 | 10.62 | 9.90 | - | - |
| Operating Margin (%) | 26.0% | 25.0% | 22.0% | 24.0% | 23.0% | - | - |
MANKIND Share Price Trend — 1-Year Movement Across Quarterly Results
Mankind Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit MANKIND share price.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
MANKIND vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Mankind Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹469,405.89 Cr | 1941.1 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 171.8 |
|
Divis Laboratories
Mar 2026 |
₹194,269.91 Cr | 7248.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 256.0 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹191,454.40 Cr | 4961.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.1 |
|
Zydus Life Science
Mar 2026 |
₹115,616.29 Cr | 1108.7 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 87.6 |
|
Cipla
Mar 2026 |
₹114,318.19 Cr | 1410.6 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 205.3 |
All amounts in ₹ Crores